Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546453 | 1.00 | ADORA3 (0.51) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL313652 | 0.91 | PDE4D (0.53) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL5203956 | 0.91 | PDE4D (0.53) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL29502689 | 0.90 | HPGD (0.48) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL6537055 | 0.89 | ADORA3 (0.53) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL25380147 | 0.89 | ADORA2A (0.51) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL14594720 | 0.89 | ADORA3 (0.50) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL13929032 | 0.89 | ADORA2A (0.51) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL471141 | 0.89 | ADORA2A (0.51) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL20991026 | 0.89 | ADORA2A (0.51) | ADORA3HPGDADORA2AHINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381820-B2 | α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside | YAMASA CORPORATION (JP) | 2008-06-03 | — | — | US | claimed |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | KOHEL YAMADA, ETAL | 2007-06-14 | — | — | US | claimed |
| EP-1676853-A1 | ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E | YAMASA CORPORATION (JP) | 2006-07-05 | — | — | EP | claimed |
| EP-4112604-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHIDROXY-3-HYDROXY-METHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | Ocuphire Pharma, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3246320-B1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHYDROXY-3- HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | REXAHN PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3378855-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHIDROXY-3-HYDROXY-METHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | Rexahn Pharmaceuticals, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-2970147-B1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R, 5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | REXAHN PHARMACEUTICALS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9920016-B2 | Process for the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one | REXAHN PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3246320-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHYDROXY-3- HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | Rexahn Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20170158662-A1 | Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One | REXAHN PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9533958-B2 | Process or the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-Enyl)-1H-pyrimidin-2-one | REXAHN PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150376142-A1 | Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One | Ocuphire Pharma, Inc. | 2015-12-31 | — | — | US | disclosed |
| US-9150520-B2 | Process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one | REXAHN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140275537-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-7381820-B2 | α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside | YAMASA CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | KOHEL YAMADA, ETAL | 2007-06-14 | — | — | US | disclosed |
| EP-1676853-A1 | ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E | YAMASA CORPORATION (JP) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376142-A1 | Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One | RXFP4, RXFP1, NPY4R | ADORA3 411/4885HPGD 2126/4885ADORA2A 622/4885 |
| US-20140275537-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE | RXFP4, RXFP1, NPY4R | ADORA3 399/4885HPGD 1911/4885ADORA2A 605/4885 |
| US-20170158662-A1 | Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One | RXFP4, RXFP1, NPY4R | ADORA3 399/4885HPGD 1911/4885ADORA2A 605/4885 |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | TYMP, PNP, DUT | ADORA3 363/4885HPGD 2654/4885ADORA2A 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.